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Abstract
Introduction: Calprotectin (MRP8/MRP14, S100A8/A9) is associated with disease activity in patients with
rheumatoid arthritis (RA). Ultrasonography (US) is a reliable method for evaluation of synovitis (B-mode (BM) and
power Doppler (PD)). The present objectives were to explore in RA patients the associations between calprotectin
and a comprehensive US examination, as well as the responsiveness of calprotectin compared to other
inflammatory markers during anti-TNF treatment.
Methods: A total of 20 RA patients starting treatment with adalimumab were examined longitudinally by US (BM
and PD (semi-quantitative scores 0 to 3) of 78 joints, 36 tendons/tendon groups and 2 bursae) and clinically at
baseline and after 1, 3, 6 and 12 months. Associations between the US sum scores and the inflammatory markers
calprotectin, serum amyloid A (SAA), CRP and ESR were explored by correlation and linear regression analyses, and
the response to treatment was assessed by Standardized Response Mean (SRM).
Results: The inflammatory markers, clinical examinations and US sum scores improved during treatment (P <
0.001). Of the inflammatory markers, calprotectin had the highest correlation coefficients with the total BM and PD
sum scores (median (range) 0.59 (0.37 to 0.76) for BM and 0.56 (0.38 to 0.72) for PD). Even higher correlations were
found between calprotectin and sum US scores of reduced number of joint counts. Calprotectin made a
considerable contribution to total US sum scores in the linear regression analyses (P = 0.001 to 0.031) and among
the inflammatory markers, calprotectin had the highest SRM (0.84 at one month).
Conclusions: Calprotectin was associated with the sum scores from a comprehensive US assessment and was
responsive to change during anti-TNF treatment. Thus, examination of this leukocyte protein could be of additional
value in the assessment of RA patients on biologic treatment.
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Introduction
Assessment of inflammatory activity is of pivotal impor-
tance for the optimal treatment of patients with rheuma-
toid arthritis (RA). Up till now the erythrocyte
sedimentation rate (ESR) and the acute phase protein C-
reactive protein (CRP) are the most widely used labora-
tory markers for evaluation of inflammatory activity in
patients with RA. Serum amyloid A (SAA) (an apo-lipo-
protein associated with high-density lipoprotein in
plasma) is produced in the liver after stimulation by the
pro-inflammatory cytokines IL-1, IL-6 and TNF-alpha,
and 1, 000-fold increases may be found during severe
inflammation [1]. Thus, it acts as an acute phase protein
like CRP, but may be more sensitive to inflammation [2].
Calprotectin is a major leukocyte protein, constituting
40 to 60% of the cytosolic protein in neutrophile granu-
locytes as well as being a major monocyte/macrophage
protein [3-5]. Calprotectin (also named MRP-8/MRP-14
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[6] and S100A8/A9 [7]) is a calcium-binding S100 pro-
tein [8] and it is one of the damage-associated molecular
pattern molecules (DAMPs) highly up-regulated in var-
ious autoimmune disorders [9]. The protein is released
during activation and turnover of leukocytes [10] and
calprotectin levels are strongly associated with disease
activity in RA patients [11,12]. Concentrations of calpro-
tectin are high in synovial fluid in RA patients in con-
trast to low levels in osteoarthritis patients [13] and
calprotectin is associated to radiographic damage and is
a predictor of radiographic progression in RA patients
[12,14].
Ultrasonography (US) is a valid and reliable tool for
detecting synovitis in patients with RA [15-17], and
joints, tendons and bursae may be examined. The extent
of synovitis is usually scored semi-quantitatively (scale 0
to 3) both for grey scale (or B-mode (BM)) synovitis
(including combined evaluation of synovial hypertrophy
and effusion) and power Doppler (PD) vascularization,
and the US scores have been shown to be sensitive for
improvement during biological treatment in RA patients
[17-20]. A recently published study from our group
showed a high degree of reliability when we used a simi-
lar scoring system as presently applied [21]. There is no
consensus on the optimal number of joints and tendons
to be assessed for US evaluation of inflammatory activity
in RA patients, but similar sensitivity to change has been
found for US examinations of different combinations of
joints and tendons during biological treatment [22].
The objectives of the present study were to examine
the associations between the levels of calprotectin and a
comprehensive as well as reduced US joint scores and
to explore the responsiveness of calprotectin compared
to other inflammatory markers during biologic treat-
ment in patients with RA.
Materials and methods
Patients
The present study is part of a work described in detail
previously [23]. In short, a comprehensive US assessment
was performed in 20 patients with RA [24] (median
(range) age 53 (21 to 78) years, disease duration 7.5 (1 to
26) years, 15 women, 70% IgM rheumatoid factor posi-
tive) the same day as they started treatment with adali-
mumab and after 1, 3, 6 and 12 months. Adalimumab (as
their first biological medication) was dosed 40 mg every
other week, all patients were on methotrexate as co-med-
ication, 14 patients used additional prednisolone (median
(range) dose 7.5 (3.75 to 15) mg) and two patients were
on daily non-steroidal anti-inflammatory drug.
The patients gave written consent according to the
Declaration of Helsinki, and the study was approved by
the local ethics committee (the regional committee for
medical and health research ethics (REK), South-East).
Laboratory examinations
The traditional inflammatory markers included ESR and
CRP (both analyzed by use of in-house standard metho-
dology, with upper normal levels of 20 mm/h for ESR
and 4 mg/l for CRP). Serum and EDTA plasma from all
the five examinations were frozen at ÷70°C for assess-
ment of SAA and calprotectin after completion of the
clinical study. SAA was measured in serum by immuno-
nephelometry using an N-Latex SAA reagent (Dade
Behring Inc., Marburg, Germany) with normal levels ≤
6.4 mg/l [25]. All plasma samples were analyzed for cal-
protectin at the same time by use of ELISA as described
previously (using kits from Calpro AS, Norway) [13,26],
with normal levels ≤ 0.91 mg/l. Assessments of calpro-
tectin in plasma have shown coefficients of variation of
5% within and 13% between assays [27].
Clinical evaluations
One of two study nurses, with more than five years
experience with joint counts in clinical studies, assessed
40 joints for tenderness and swelling (proximal interpha-
langeal 1 to 5, metacarpophalangeal 1 to 5, wrist, elbow,
shoulder, knee, ankle and metatarsophalangeal 1 to 5)
and they scored the global disease activity caused by RA
on a VAS scale (assessor’s global VAS). They were
blinded for the results of the US examinations. Patient’s
evaluation of disease activity was assessed (VAS), and
DAS28 [28] was calculated.
Ultrasonography
All patients were assessed by extensive US examinations
(performed by one experienced sonographer, HBH) with
use of a 5 to 13 MHz probe (Siemens Antares, Sonoline,
Siemens Medical Solutions, 1230 Shorebird Way Moun-
tain, CA, USA) with fixed settings optimal for power Dop-
pler signals in more superficial joints. The joints assessed
bilaterally by use of standard projections [29] included
proximal interphalangeal 1 to 5, metacarpophalangeal 1 to
5, carpometacarpal 1 to 5, wrist (radiocarpal, intercarpal
and radioulnar joints), elbow, shoulder (glenohumeral and
acromioclavicular joints) hip, knee, ankle (talocrural joint),
4 major foot joints (talonavicular, subtalar, calcaneocuboi-
dal and cuneonavicular joints), tarsometatarsal 1 to 5,
metatarsophalangeal 1 to 5 and the interphalangeal joint
of the first toe (a total of 78 joints), in addition to tendons
bilaterally in the wrists (at the level of the radiocarpal
joint: all the 6 compartments dorsally and the flexor digi-
torum superficialis and profundus, flexor pollicis longus
and flexor carpi radialis tendons at the palmar side), in the
ankles (at the level of the malleol and distal tibia; medial,
anterior and lateral tendon groups) as well as the long
biceps tendon (a total of 36 tendons or tendon groups)
and subdeltoid bursa bilaterally. The arthritis, tenosynovi-
tis and bursitis were all scored for BM presence of synovial
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hypertrophy and fluid (combined) and presence of vascu-
larization (PD) on a 4-point scale: 0 = none, 1 = minor, 2
= moderate or 3 = major presence. The US examiner was
blinded for US results from the previous examinations as
well as for the results from the clinical joint assessments
and laboratory tests performed the same day.
Statistics
Wilcoxon signed rank test was used to examine changes
from baseline of the US, clinical and laboratory results
during follow-up. Correlations were analyzed by use of
Spearman’s rank correlations. Linear regression analysis
was performed for all examinations with total sum score
BM or sum score PD as the dependent variable with
age, sex, disease duration and DAS28 as well as each of
the biomarkers (one at a time) as the independent vari-
ables. A P-value < 0.05 was considered statistically sig-
nificant. The responsiveness to change was explored by
calculation of the Standardized Response Mean (SRM)
as the mean change divided by the SD of the change
(definitions of SRM results: < 0.50 = small, 0.50 to 0.80
= moderate and > 0.80 = large responses).
Results
The laboratory, clinical and US results improved signifi-
cantly during the study (Table 1). Significant cross-
sectional correlations were found between the inflamma-
tory biomarkers and both BM and PD total sum scores at
most of the examinations, with calprotectin having the
highest correlation coefficients (Table 2). Figure 1 illus-
trates the associations between calprotectin and total
sum US results at baseline and after three months. Of the
correlation analyses between calprotectin levels and US
sum scores of different reduced numbers of joints and
tendons (the 7-, 12-, 28- and 44-joint scores [22]), the
12-joint score was found to have the highest correlation
coefficients at different examinations (median (range)
0.59 (0.53 to 0.83) (P = 0.02 to < 0.001) for BM and 0.58
(0.42 to 0.72) (P = 0.06 to < 0.001) for PD).
To assess the validity of the US examination, the 28
joints included in the DAS28 were explored for similar-
ity in detecting arthritis by correlating the number of
joints identified by clinical evaluation of swelling (yes vs.
no) and BM score (≥ 1 vs. 0). The median (range) corre-
lations were 0.58 (0.43 to 0.85) (P = 0.06 to < 0.001).
When the sum BM scores of the 28 joints were corre-
lated with the number of joints with clinical swelling,
even higher coefficients were found (0.67 (0.48 to 0.87)
(P = 0.03 to < 0.001).
The median (range) correlation coefficients between
the inflammatory biomarkers and assessors global VAS
(at the five examinations) were 0.55 (0.37 to 0.74) for
Table 1 Median (range) of the laboratory, clinical and US scores
Baseline 1 month 3 months 6 months 12 months
Calprotectin, mg/l (normal ≤ 0.9l) 2.02 (0.56 to 20.44) 0.92 (0.32 to 18.86)** 0.93 (0.28 to 6.30)** 0.94 (0.24 to 22.02)** 1.08 (0.36 to 17.60)
SAA mg/l (normal
≤ 6.4)
10.60 (2.17 to 300) 6.94 (1.37 to 270)* 4.19 (0.70 to 38.5)** 4.39 (1.61 to 176)* 8.37 (1.12 to 136)
CRP, mg/l
(normal ≤ 4)
4.5 (1 to 136) 2.0 (1 to 163) 2.5 (1 to 26)** 2.5 (1 to 78) 4.5 (1 to 86)
ESR, mm/h
(normal ≤ 20)
20 (3 to 67) 13 (3 to 108)** 14.5 (2 to 65)** 14.5 (5 to 99) 17.5 (3 to 78)
DAS28 5.32 (3.40 to 7.70) 4.20 (1.56 to 8.90)** 4.26 (0.83 to 7.02) ** 4.36 (1.59 to 7.58)** 4.33 (1.40 to 6.60)**
Assessors VAS 26 (6 to 55) 15 (4 to 52)* 14 (3 to 40)** 11 (2 to 57) 10 (3 to 44)**
No of swollen joints (of 40) 8 (1 to 19) 5 (0 to 22) 6 (0 to 16)** 4 (0 to 16)* 4 (0 to 14)**
No of tender joints (of 40) 12 (0 to 23) 9 (0 to 35) 7 (0 to 16)** 6 (0 to 16)** 7 (0 to 21)**
BM score 53 (6 to 151) 39 (3 to 121)** 35 (6 to 94)** 24 (0 to 86)** 27 (1 to 96)**
PD score 33 (0 to 119) 21 (0 to 83)** 16 (2 to 53)** 14 (0 to 76)** 13 (0 to 72)**
*P < 0.05, **P < 0.01 (Wilcoxon signed rank test for changes from baseline to the different follow-up examinations).
BM, B-mode; CRP, C-reactive protein; DAS28, Disease Activity Score 28 joints; ESR, erythrocyte sedimentation rate; PD, power Doppler; SAA, serum amyloid A;
Assessors VAS, assessors global disease activity score on a visual analogue scale (0 to 100).
Table 2 Spearman’s rank correlations between the laboratory variables and sum B-mode/power Doppler scores
Baseline 1 month 3 months 6 months 12 months
Calprotectin 0.45*/0.38 0.37/0.53* 0.76**/0.72** 0.60**/0.56* 0.59**/0.60**
SAA 0.42/0.37 0.30/0.30 0.58**/0.37 0.61**/0.51* 0.48*/0.45*
CRP 0.33/0.34 0.04/0.11 0.49*/0.35 0.59**/0.43 0.57**/0.55*
ESR 0.37/0.48* 0.36/0.35 0.45*/0.42 0.32/0.33 0.35/0.40
*P < 0.05, **P < 0.01
CRP, C-reactive protein; ESR, erythrocyte sedimentation rate; SAA, serum amyloid-A
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calprotectin, 0.57 (0.41 to 0.73) for SAA, 0.59 (0.39 to
0.80) for CRP and 0.45 (0.33 to 0.65) for ESR (correla-
tion coefficients ≥ 0.43 = P < 0.05).
Both calprotectin and CRP contributed significantly
to explain total sum score BM as the dependent vari-
able in linear regression analyses performed for all
examinations during the study (P = 0.001 to 0.017 for
calprotectin and P = 0.012 to 0.038 for CRP), SAA
contributed significantly at baseline and six months
(P = 0.045 and 0.032) and ESR at one and three
months (P = 0.030 and 0.048). With total sum score
PD as the dependent variable, calprotectin contribu-
ted significantly at all examinations (P = 0.003 to
0.031), CRP contributed significantly at baseline, 6
and 12 months (P = 0.001 to 0.026), SAA at 6 months
(P = 0.002) and ESR at 3 and 6 months (P = 0.007
and 0.044).
Calprotectin was found to have higher responsiveness
to change than CRP, SAA and ESR (Table 3), with large
SRM at 1 month, moderate at 3 and 6 months and
small at 12 months examination.
Discussion
To our knowledge, this is the first study to examine the
associations between levels of calprotectin and BM/PD
scores from a comprehensive US examination. All the
inflammatory biomarkers, clinical assessments and US
sum scores improved during treatment with adalimu-
mab. Significant correlations were found between the
levels of calprotectin and the US scores and the validity
of calprotectin as an inflammatory marker was sup-
ported by associations with the clinical evaluation of dis-
ease activity. In addition, calprotectin was found to have
substantial responsiveness to biological treatment.
 
 
 
Figure 1 Scatterplots of calprotectin levels with corresponding sum B-mode (BM) or power Doppler (PD) scores. The scatterplots
illustrate the distribution of the calprotectin levels with the corresponding total sum B-mode (BM) or power Doppler (PD) scores at baseline and
at three months examination.
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Calprotectin is released from leukocytes during
inflammation. Thus the present objective was to per-
form an extensive US examination of joints, tendons
and bursae to capture the total amount of inflammation.
However, the scoring system does not differ between
small and large joints. Hence, adjusting for the joint size
could have improved the correlations between calprotec-
tin levels and sum US scores. When reduced numbers
of joints were analyzed, higher coefficients were found.
The strongest correlations were found with the 12-joint
score [17], which includes bilateral examination of the
elbow, wrist, MCP 2 and 3, knee and ankle in addition
to the medial and lateral tendon compartments in the
ankle. Thus, in this score most of the joints are rela-
tively large, which may explain the stronger correlations
with calprotectin.
The correlations between the laboratory markers and
the total sum US scores increased during the study, with
highest coefficients between calprotectin and US scores
(both comprehensive and reduced number of joints) at the
three-month examination (Figure 1). Calprotectin levels
have been found to reflect the ongoing inflammation, and
at the three-month examination both calprotectin and the
US detected synovitis were significantly reduced. Since
this is a small study, the different levels of association
between calprotectin and US pathology during biologic
medication should be explored in larger studies.
Calprotectin is expressed in synovial tissue macro-
phages localized in the lining layer adjacent to the carti-
lage-pannus junction [30] and high levels of calprotectin
have been found in synovial fluid from RA patients [13].
Calprotectin is suggested to play an active role in the
inflammation by amplifying pro-inflammatory cytokine
responses via activation of NF-B and p38 mitogen-acti-
vated protein kinase in RA [31]. Calprotectin has been
shown to be a reliable marker of inflammation in several
rheumatic joint diseases like RA [11,12], juvenile idio-
pathic arthritis [32,33] and psoriatic arthritis [34]. The
present study indicates that calprotectin levels are asso-
ciated with the overall inflammation in RA patients,
including both the amount of synovial hypertrophy
explored by BM and the extent of vascularization evalu-
ated by PD.
The regression analyses showed calprotectin to be
independently associated with both total sum BM and
PD scores, even when DAS28 was included in the equa-
tion. Thus, calprotectin was able to give information
beyond a clinical composite score. Subclinical inflamma-
tion is of major importance in the evaluation of RA
patients, and both BM and PD activity have been
described in RA patients being in clinical remission [35].
A recent study of patients with juvenile idiopathic
arthritis in remission showed that the level of calprotec-
tin was associated with risk of relapse after discontinu-
ing methotrexate [36]. A definition of clinical remission
in RA was recently presented by ACR and EULAR [37].
The present finding of associations between calprotectin
and the US sum scores suggest that in RA patients a
normal calprotectin level could support a clinical evalua-
tion of remission. This important issue should be
further explored.
PD activity has been found to be related to the develop-
ment of joint erosions [38] and we have previously found
calprotectin to be associated with radiographic damage
[12,14]. Calprotectin plays a major role in the local
inflammatory process during RA [9,31], and the possible
association between PD activity and calprotectin levels
should, therefore, be investigated in a larger study.
The evaluation of US synovitis scores is dependent on
the operator. Much work has been done to improve the
reliability of US scoring [15-17]. For the joint scores
included in the present study there were high intra-
reader intra-class correlations for evaluation of stored
images (described previously [23]). In addition, the pre-
sent BM and PD joint scoring was similar to the scoring
system used in a US atlas recently applied in a reliability
study where we found high intra- and inter- reader
reliability [21].
Strengths of the present longitudinal study were that
only one experienced sonographer performed the com-
prehensive US assessments and that all the RA patients
used a biologic medication supposed to cause improve-
ment. However, an obvious weakness is the limited
number of patients included.
Conclusions
Calprotectin was found to have high association to US
assessments of RA patients, indicating that calprotectin
reflects ongoing inflammation. In addition, calprotectin
levels decreased during treatment with adalimumab, and
had higher sensitivity to change than the traditional
inflammatory markers. In contrast to the acute phase
proteins being produced in the liver, calprotectin is
released from activated leukocytes during inflammation.
Our results support that calprotectin may be used as a
marker of inflammatory activity in RA patients on biolo-
gic treatment.
Table 3 Standardized response mean (SRM) of the
changes from baseline of the four laboratory markers
SRM
1 month
SRM
3 months
SRM
6 months
SRM
12 months
Calprotectin -0.84 -0.63 -0.63 -0.32
SAA -0.44 -0.55 -0.38 -0.30
CRP -0.10 -0.43 -0.15 -0.12
ESR -0.33 -0.71 -0.03 -0.13
CRP, C-reactive protein; ESR, erythrocyte sedimentation rate; SAA, serum
amyloid-A.
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